Drug intelligence / Profile preview

ATSOlona

Development stage: Unknown
Lead developer: ATsoPharma

Overview

ATSOlona is a next-generation therapeutic candidate developed by ATsoPharma for the treatment of human papillomavirus (HPV) infections, precancerous lesions, and cervical uterine cancer. The drug is designed to provide rapid clinical results, with significant therapeutic effects observed in less than two months of treatment. According to the developer, ATSOlona is characterized by a favorable safety profile with no relevant side effects and no negative impact on women's sexual health. As of the latest pipeline reports, the candidate has completed pre-clinical and formula development and has transitioned into Phase 1 clinical trials.

Beyond the preview

Go deeper on ATSOlona.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATSOlona.

Explore the full profile